Boise Cascade Company (BCC) Drops 6.78% on January 07

Equities Staff |

Boise Cascade Company (BCC) was one of the Russell 2000's biggest losers for Thursday January 07 as the stock slid 6.78% to $21.45, a loss of $-1.56 per share. Starting at an opening price of $22.65 a share, the stock traded between $20.96 and $22.90 over the course of the trading day. Volume was 619,158 shares over 5,217 trades, against an average daily volume of 357,269 shares and a total float of 38.82 million.

The losses send Boise Cascade Company down to a market cap of $832.78 million. In the last year, Boise Cascade Company has traded between $43.90 and $22.89, and its 50-day SMA is currently $28.49 and 200-day SMA is $32.34.

The stock has a P/E Ratio of 13.9.

Boise Cascade Co manufactures engineered wood products, plywood, lumber and particleboard. The Company also distributes building materials, including wood products manufactured by its wood products division.

Boise Cascade Company is based out of Boise, ID and has some 5,820 employees. Its CEO is Thomas K. Corrick.

For a complete fundamental analysis analysis of Boise Cascade Company, check out’s Stock Valuation Analysis report for BCC. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

MyForce, Inc.

As parents, we constantly worry about the safety of our loved ones. The media bombards us with incidents from across the nation school shootings, frequent assaults on campuses, and crimes…


Our mission is to be the best place for people who care about music to create and discover thoughtfully curated playlists. In essence, 8tracks is a platform for online mixtapes.